Phase 1b study of obinutuzumab, ibrutinib, and venetoclax in relapsed and refractory chronic lymphocytic leukemia

Targeted therapies including the engineered afucosylated anti-CD20 monoclonal antibody obinutuzumab, Bruton’s tyrosine kinase inhibitor ibrutinib, and B-cell lymphoma protein 2 inhibitor venetoclax have demonstrated significant clinical activity in chronic lymphocytic leukemia (CLL) and, based on th...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Blood
Hlavní autoři: Rogers, Kerry A., Huang, Ying, Ruppert, Amy S., Awan, Farrukh T., Heerema, Nyla A., Hoffman, Corinne, Lozanski, Gerard, Maddocks, Kami J., Moran, Mollie E., Reid, Mark A., Lucas, Margaret, Woyach, Jennifer A., Whitlow, W. Thomas, Jones, Jeffrey A., Byrd, John C.
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society of Hematology 2018
Témata:
Clinical Trials and Observations
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6182267/
https://ncbi.nlm.nih.gov/pubmed/30111609
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2018-05-853564
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky